Literature DB >> 14614320

Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line.

Lin Qi1, Rana P Singh, Yingnian Lu, Rajesh Agarwal, Gail S Harrison, Alex Franzusoff, L Michael Glode.   

Abstract

Silibinin, derived from milk thistle extract, has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, and to alter cell cycle regulators. Alteration in pathways regulating cell growth likely account for silibinin's inhibition of tumor growth. Since the epidermal growth factor receptor (EGFR) is a key regulator in cell signaling pathways, in the present study we directly tested the hypothesis that the EGFR plays a key role in mediating silibinin cytotoxicity to cancer cells. We generated a cell line, 9L-EGFR, which stably expressed human EGFR; the parental rat glioma cell line, 9L, does not contain endogenous EGFR message or protein. Our results show that expression of EGFR was both necessary and sufficient for conferring toxicity in response to silibinin in 9L-EGFR cells. Addition of silibinin was shown to inhibit EGFR activation by EGF in 9L-EGFR cells. These studies support the hypothesis that silibinin toxicity to cancer cells involves the EGFR signaling pathway. The findings presented here provide a rationale for understanding the growth inhibition effect of silibinin in cancer cells, and warrant further investigation into the effect of silibinin on specific pathways of cell signaling mediated by the EGF receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614320     DOI: 10.4161/cbt.2.5.452

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

1.  Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin.

Authors:  Alex E Grill; Brenda Koniar; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

2.  Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3.

Authors:  Munenori Takaoka; Hideki Harada; Claudia D Andl; Kenji Oyama; Yoshio Naomoto; Kelly L Dempsey; Andres J Klein-Szanto; Wafik S El-Deiry; Adda Grimberg; Hiroshi Nakagawa
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

Review 3.  Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

Review 4.  Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Authors:  Harold Ting; Gagan Deep; Rajesh Agarwal
Journal:  AAPS J       Date:  2013-04-16       Impact factor: 4.009

5.  Silibinin inhibits glioma cell proliferation via Ca2+/ROS/MAPK-dependent mechanism in vitro and glioma tumor growth in vivo.

Authors:  Kwang Won Kim; Chang Hwa Choi; Thae Hyun Kim; Chae Hwa Kwon; Jae Suk Woo; Yong Keun Kim
Journal:  Neurochem Res       Date:  2009-03-05       Impact factor: 3.996

6.  Kava, a tonic for relieving the irrational development of natural preventive agents.

Authors:  Rajesh Agarwal; Gagan Deep
Journal:  Cancer Prev Res (Phila)       Date:  2008-11

7.  Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells.

Authors:  Marjan Gharagozloo; Zahra Amirghofran
Journal:  J Cancer Res Clin Oncol       Date:  2007-04-14       Impact factor: 4.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.